AU2008319366B2 - Benzomorpholine derivatives and methods of use - Google Patents

Benzomorpholine derivatives and methods of use Download PDF

Info

Publication number
AU2008319366B2
AU2008319366B2 AU2008319366A AU2008319366A AU2008319366B2 AU 2008319366 B2 AU2008319366 B2 AU 2008319366B2 AU 2008319366 A AU2008319366 A AU 2008319366A AU 2008319366 A AU2008319366 A AU 2008319366A AU 2008319366 B2 AU2008319366 B2 AU 2008319366B2
Authority
AU
Australia
Prior art keywords
compound
usa
compounds
agents
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008319366A
Other languages
English (en)
Other versions
AU2008319366A1 (en
Inventor
Mina Dilmeghani Seran
Jean-Christophe Harmange
Jay Larrow
Matthew W. Martin
Joseph F. Payack
Raju Subramanian
Yohannes Teffera
Ryan White
Roger Zanon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2008319366A1 publication Critical patent/AU2008319366A1/en
Application granted granted Critical
Publication of AU2008319366B2 publication Critical patent/AU2008319366B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2008319366A 2007-10-29 2008-10-28 Benzomorpholine derivatives and methods of use Ceased AU2008319366B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94807P 2007-10-29 2007-10-29
US61/000,948 2007-10-29
PCT/US2008/012224 WO2009058267A2 (en) 2007-10-29 2008-10-28 Benzomorpholine derivatives and methods of use

Publications (2)

Publication Number Publication Date
AU2008319366A1 AU2008319366A1 (en) 2009-05-07
AU2008319366B2 true AU2008319366B2 (en) 2012-03-01

Family

ID=40394086

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008319366A Ceased AU2008319366B2 (en) 2007-10-29 2008-10-28 Benzomorpholine derivatives and methods of use

Country Status (8)

Country Link
US (1) US7795254B2 (enExample)
EP (1) EP2220078B1 (enExample)
JP (1) JP5343082B2 (enExample)
AU (1) AU2008319366B2 (enExample)
CA (1) CA2703257C (enExample)
ES (1) ES2417009T3 (enExample)
MX (1) MX2010004620A (enExample)
WO (1) WO2009058267A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH684182A5 (de) 1991-10-15 1994-07-29 Escher Wyss Ag Rotationsdruckmaschine.
MX2012013331A (es) 2010-05-19 2013-02-01 Sandoz Ag Purificacion de posaconazol y de intermediarios de posaconazol.
BR112012029225B1 (pt) 2010-05-19 2020-10-27 Sandoz Ag processo para a preparação de um composto quiral, composto quiral e uso de um composto quiral
JP2013532131A (ja) * 2010-05-19 2013-08-15 サンド・アクチエンゲゼルシヤフト ポサコナゾール中間体の製造
US9493428B2 (en) 2011-06-16 2016-11-15 Sandoz Ag Process for the preparation of a chiral compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070891A2 (en) * 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US4916135A (en) * 1989-05-08 1990-04-10 Hoechst Roussel Pharmaceuticals Inc. N-heteroaryl-4-quinolinamines
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
WO1996023774A1 (en) 1995-01-31 1996-08-08 Zenyaku Kogyo Kabushiki Kaisha Thioquinoline derivatives
GB9505651D0 (en) 1995-03-21 1995-05-10 Agrevo Uk Ltd AgrEvo UK Limited
GB9505702D0 (en) 1995-03-21 1995-05-10 Agrevo Uk Ltd Fungicidal compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
EP0860433B1 (en) * 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
DE69613211T2 (de) * 1995-11-14 2001-11-15 Pharmacia & Upjohn S.P.A., Mailand/Milano Aryl- und heteroaryl- purin- und pyridopyrimidin- derivate
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19614718A1 (de) * 1996-04-15 1997-10-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
ATE293102T1 (de) * 1998-04-23 2005-04-15 Takeda Pharmaceutical Naphthalene derivate ,ihre herstellung und verwendung
DE69924500T2 (de) * 1998-08-21 2006-02-09 Parker Hughes Institute, St. Paul Chinazolinderivate
EE05708B1 (et) * 1999-02-10 2014-04-15 Astrazeneca Ab Kinasoliini derivaat angiogeneesi inhibiitorina ja selle kasutamine
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
KR20010110750A (ko) * 1999-04-12 2001-12-13 앤드류 앵뉴 인테그린 길항제로서의 치환된 비사이클릭 헤테로아릴화합물
WO2002030924A1 (en) * 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
CN1308310C (zh) * 2000-10-20 2007-04-04 卫材R&D管理有限公司 含氮芳环衍生物
KR100883731B1 (ko) * 2001-06-22 2009-02-12 기린 파마 가부시끼가이샤 간세포 증식 인자 수용체 자기 인산화를 저해하는 퀴놀린유도체 및 퀴나졸린 유도체 및 이들을 함유하는 의약 조성물
MXPA04004219A (es) * 2001-11-03 2004-09-10 Astrazeneca Ab Derivados de quinazolina como agentes antitumorales.
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
WO2003064413A1 (en) * 2002-02-01 2003-08-07 Astrazeneca Ab Quinazoline compounds
US7645878B2 (en) * 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
DE60329910D1 (de) * 2002-03-29 2009-12-17 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
EP1548008A4 (en) * 2002-08-23 2008-08-06 Kirin Pharma Kk COMPOUND WITH TGF-BETA-HEMMENDER EFFECT AND THIS MEDICAL COMPOSITION CONTAINING
US7320989B2 (en) * 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
WO2004078114A2 (en) * 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
US7312330B2 (en) * 2003-12-24 2007-12-25 Renovis, Inc. Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070891A2 (en) * 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use

Also Published As

Publication number Publication date
EP2220078A2 (en) 2010-08-25
JP5343082B2 (ja) 2013-11-13
AU2008319366A1 (en) 2009-05-07
ES2417009T3 (es) 2013-08-05
JP2011502147A (ja) 2011-01-20
MX2010004620A (es) 2010-07-28
WO2009058267A3 (en) 2010-06-10
WO2009058267A2 (en) 2009-05-07
EP2220078B1 (en) 2013-05-22
US7795254B2 (en) 2010-09-14
CA2703257C (en) 2013-02-19
US20090149454A1 (en) 2009-06-11
CA2703257A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
US7687522B2 (en) Substituted pyridines and pyrimidines and their use in treatment of cancer
EP1881976B1 (en) Substituted amide derivatives as protein kinase inhibitors
EP3170824B1 (en) A 6-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl)-1,6-naphthyridin-5(6h)-one derivative as c-met inhibitor
EP2118069B1 (en) Bis-aryl amide derivatives useful for the treatment of cancer
EP2125780B1 (en) Substituted heterocycles and methods of use
AU2009248839B2 (en) Heterocycles as protein kinase inhibitors
AU2008319366B2 (en) Benzomorpholine derivatives and methods of use
HK1116161B (en) Substituted amide derivatives as protein kinase inhibitors

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ PAYACK, JOSEPH F.; SUBRAMANIAN, RAJU; MARTIN, MATTHEW W.; TEFFERA, YOHANNES; LARROW, JAY; ZANON, ROGER; DILMEGHANI SERAN, MINA; HARMANGE, JEAN-CHRISTOPHE AND WHITE, RYAN.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTORS TO READ WHITE, RYAN; PAYACK, JOSEPH F.; LARROW, JAY; TEFFERA, YOHANNES; HARMANGE, JEAN-CHRISTOPHE; DILMEGHANI SERAN, MINA; SUBRAMANIAN, RAJU; ZANON, ROGER AND MARTIN, MATTHEW W.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired